Post on 18-Jan-2016
transcript
US-Nanotechnology Characterization LabScott McNeil, PhD
Director
Workshop Session 7: EU-US and International cooperation
NMBP 14-2017: Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials
Thematic brokerage workshopsWorkshop 7: EU-U.S Cooperation
EU Brokerage Event on Kets in Horizon 2020Strasbourg, 1st October 2015
101/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
US-NCL Mission
201/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
The NCL was established in 2004 as an interagency collaboration among NCI, NIST, and FDA. The lab’s primary mission has been to accelerate the translation of promising nanotech cancer drugs and
diagnostics using a standardized “Assay Cascade.
Big Pharma
Academic PIs
Biotech Companies
Government
R & D Community
In Vivo Characterization
In Vitro Characterization
Physicochemical Characterization
Clinical
Regulatory
Commercialization
Support
Assay Cascade
301/10/2015 - BE KETs
• Equivalence testing for nanosimilars • Addressing FDA’s scientific questions• NBCDs
• Collaborations with Pharma, CMOs & industry consortia
• Immunotox• Active targeting
• Working with instrument manufacturers
• Provides “pharmaceutical mentorship” for materials scientists and engineers
• Other indications, EHS, etc.
401/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
Over 300 Nanomaterials Characterized
Types of Samples
• NCL has characterized over 300 different nanomaterials and a wide range of various platforms.
• NCL has an average of 15 active collaborations at any given time.
• NCL characterizes an average of 75 samples each year.
• NCL testing is tailored to the platform properties, API, route of administration, and intended therapeutic outcome of the individual nanomedicine.
NCL testing links physicochemical properties to biological outcomes.
5
In clinical trials
601/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
NCL-FDA RelationshipNCL is trusted source for preclinical data on nanomaterials.
• NCL allows FDA to preview what’s in pipeline for nanotech INDs/IDEs.
• Quarterly interactions (visits, working groups) with FDA to maintain collaboration.
• Collaborations with FDA to fill gaps/better inform regulatory process: methods development, basic research and grand challenges
• Addressing regulatory concerns facilitates commercialization.
• FDA provides input on NCL’s assay cascade and is represented on NCL’s scientific oversight committee.
• NCL participates in FDA public meetings on topics related to nanomedicine.
701/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
NCL Supports Translation/Regulation
• Preclinical Characterization
• Regulatory Concerns
• Clinical Characterization
• Exploring Alternate Indications
• Next-Generation Nanoparticles
Historical NCL knowledge used to make recommendations in many areas, helping sponsors gain regulatory approval.
Nanomedicine Developers
801/10/2015 - BE KETs
NCL-FDA Scientific Collaborations
• Immunological reactions to nanomaterials in non-human primates.
• Dermal penetration of nanomaterials in sunscreens and cosmetics.
• Compared endotoxin levels in experimental nanomaterial products to levels in FDA-approved products.
• Penetration of nanoscale TiO2 particles in rodents, pig skin, and human skin.
• Characterization and purification of dendrimers for a dermal penetration study.
• Effects of sterilization procedures (autoclave, gamma irradiation, etc.) on silver colloids.
• Upcoming collaboration to study bioequivalence of follow-on nanomedicine products.
Office of Generic Drugs
Endotoxin screening should be included whenever biological assessments of the materials are going to be performed.
NCL pre-screened all ENMs used in this study.
NCL ParticleDesignation
Nanomaterial
Endotoxin, Kinetic Turbidity LAL
First test lots
New, Large-scale lots
NIEHS-120 nm, citrate
stabilized silver42.7 EU/mL < 0.5 EU/mL
NIEHS-220 nm, PVP
stabilized silver113 EU/mL ≤ 2.2 EU/mL
NIEHS-3110 nm, citrate stabilized silver
0.42 EU/mL < 0.5 EU/mL
NIEHS-4110 nm, PVP
stabilized silver144 EU/mL < 0.5 EU/mL
9
Coordination between Agencies
Characterization in pristine vs. biological setting matters.
BET = Brunauer, Emmet, and Teller
10
Vendor used BET for measuring size –BET is a surface area measurement, not accurate for size measurements.
Formula: CeO2
Purity: 99.5% minimum (based on rare earth oxide impurities)Formula Weight: 172.12 g/molMelting Point: 2600°CDensity: 7.132 g/mL
Form: 15-30 nm average particle size, powder
Manufacturer-Stated Specs:
What the Material Actually Looks Like:
• Micron-sized aggregates/agglomerates• Largely insoluble in aqueous media
Pristine vs. Biological Settings
Transmission EM
Scanning EM
Centrifugal Field-Flow Fractionation
CNTs will exist in a variety of sizes, shapes, and agglomeration states.
Vendor specs: OD 10-20 nm, length 0.5-2 μm
Vendor specs
Reality
11
Manufacture vs. Experimental
12
• Need better protocols for dispersing poorly soluble ENMs; better reproducibility between labs.
• Many labs will sonicate and use immediately, (hopefully) before ENMs settle out.
• Some add coatings to help solubilize, but can these influence other factors.
Problem: Poorly soluble ENMs
This is an important step in correlating PCC to biological properties.
Recommendations
13
• Very limited PCC and size tools are available for many poorly soluble ENMs.
• Most require an aqueous resuspension.
• For example, MWCNTs typically only report TEM measurements on a very select population.
Problem: Limited characterization tools
Need consistency across labs in measuring and reporting PCC.
• How should size of polydispered samples be reported?• Size by XRD vs TEM vs DLS can all be very different.
Problem: Size reporting for polydispersed samples
Recommendations
29/11/2013 - BE KETs Adressed challenge/PPP 14
Systematic investigations of the mechanisms and effects of engineered nanomaterial interactions with living systems and/or the environment36 partners across the globe working together to study more than two dozen different ENMs
NCL’s Role, Testing 15 ENMsPhysicochemical Characterization
• Size/Size Distribution• DLS• TEM
• Surface Charge• Zeta Potential
• Composition• EDS
In Vitro Cytotoxicity• MTT Cell Viability Assay• LDH Membrane Integrity Assay
• Porcine Renal Proximal Tubule (LLC-PK1) Cells• Human Hepatocellular Carcinoma (HepG2) Cells
1501/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
Cooperation with EU-NCLExpansion of resources for nanomedicine developers.
•Expanded visibility
•Greater quality control & harmonization
• Reduced risk of an adverse event in nanomedicine• EU-NCL will facilitate interaction with EMA
NCL will work closely with EU-NCL to establish SOPs, keep lines of communication open.
Contact Person: Scott McNeil, PhDDirector
Organisation Nanotechnology Characterization Laboratory
AddressP.O. Box BFrederick, MD 21703United States
Phone nr (301) 846-6939
E-mail ncl@mail.nih.gov
1601/10/2015 - BE KETs Regulatory Science Framework for Nanomedicines and Biomaterials
Contact Details